Literature DB >> 15673781

Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice.

Brad Spellberg1, Yue Fu, John E Edwards, Ashraf S Ibrahim.   

Abstract

We studied the combination of amphotericin B lipid complex (ABLC) and caspofungin in mice with disseminated Rhizopus oryzae. Combination therapy improved survival compared to that of mice given monotherapy and that of untreated controls (P < 0.05) but did not improve organ clearance. In addition, prophylactic combination therapy was not more effective than prophylactic ABLC alone.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15673781      PMCID： PMC547325          DOI： 10.1128/AAC.49.2.830-832.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto).

Authors:  L Pagano; P Ricci; A Tonso; A Nosari; L Cudillo; M Montillo; A Cenacchi; L Pacilli; F Fabbiano; A Del Favero
Journal:  Br J Haematol       Date:  1997-11       Impact factor: 6.998

2.  A multiple comparisons sign test: all pairs of treatments.

Authors:  A L Rhyne; R G Steel
Journal:  Biometrics       Date:  1967-09       Impact factor: 2.571

Review 3.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

4.  Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Authors:  Ashraf S Ibrahim; Valentina Avanessian; Brad Spellberg; John E Edwards
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

5.  Rhinocerebral mucormycosis: a report of eleven cases.

Authors:  P Chetchotisakd; P Boonma; M Sookpranee; C Pairojkul
Journal:  Southeast Asian J Trop Med Public Health       Date:  1991-06       Impact factor: 0.267

6.  Rhinocerebral mucormycosis.

Authors:  G Cruickshank; R D Vincent; H M Cherrick; K Derby
Journal:  J Am Dent Assoc       Date:  1977-12       Impact factor: 3.634

7.  Rhinocerebral mucormycosis: results of aggressive surgical debridement and amphotericin B.

Authors:  J W Ochi; J P Harris; J I Feldman; G A Press
Journal:  Laryngoscope       Date:  1988-12       Impact factor: 3.325
  7 in total
  40 in total

1.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 2.  Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Authors:  Clifford Quan; Brad Spellberg
Journal:  Proc Am Thorac Soc       Date:  2010-05

3.  Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.

Authors:  Caitlin Reed; Ashraf Ibrahim; John E Edwards; Irwin Walot; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

4.  Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.

Authors:  María Guembe; Jesús Guinea; Teresa Peláez; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

5.  In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.

Authors:  Nikolaos G Almyroudis; Deanna A Sutton; Annette W Fothergill; Michael G Rinaldi; Shimon Kusne
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

6.  Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis.

Authors:  Alexis Soummer; Armelle Mathonnet; Olivier Scatton; Pierre Philippe Massault; André Paugam; Virginie Lemiale; Jean Paul Mira; Eric Dannaoui; Alain Cariou; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

7.  In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.

Authors:  Eric Dannaoui; Patrick Schwarz; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 8.  The role of fungi in diseases of the nose and sinuses.

Authors:  Zachary M Soler; Rodney J Schlosser
Journal:  Am J Rhinol Allergy       Date:  2012 Sep-Oct       Impact factor: 2.467

9.  Zygomycosis: an emerging fungal infection with new options for management.

Authors:  Carol A Kauffman; Anurag N Malani
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

10.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.